Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.

The Prostate - 1 May 2010

Karanikolas Breanne D W, Figueiredo Marxa L, Wu Lily

Abstract excerpt

BACKGROUND: Although most prostate cancers respond well to initial treatments, a fraction of prostate cancers are more aggressive and will recur and metastasize. At that point, there are few treatment options available. Significant efforts have been made to identify biomarkers that will identify these more aggressive cancers to tailor a more vigorous treatment in order to improve outcome. Polycomb Group protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Androgens
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lentivirus

Share to Neoplasm Invasiveness

Share to Neoplasm Staging

Share to Polycomb Repressive Complex 2

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20087897
DOI: 10.1002/pros.21112
PMCID: PMC2848714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.PMID 20087897Read ↗

The polycomb group protein EZH2 is involved in progression of prostate cancer.Semantic proximity Read ↗

Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancerSemantic proximity Read ↗

Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell LineSemantic proximity Read ↗

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancerSemantic proximity Read ↗

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read ↗

Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor-Propagating Cells in Prostate CancerSemantic proximity Read ↗

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersSemantic proximity Read ↗

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsSemantic proximity Read ↗

Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancerSemantic proximity Read ↗

A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer OutcomeSemantic proximity Read ↗

Androgens Suppress EZH2 Expression Via Retinoblastoma (RB) and p130-Dependent Pathways: A Potential Mechanism of Androgen-Refractory Progression of Prostate CancerSemantic proximity Read ↗

Polycomb-mediated silencing in neuroendocrine prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.